Abstract
469P - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have